Corbus 15min chart shows KDJ Death Cross and Bearish Marubozu signal.

Friday, Jul 18, 2025 12:18 pm ET1min read

The 15-minute chart of Corbus has exhibited a bearish trend, as evidenced by a KDJ Death Cross and a Bearish Marubozu pattern on July 18, 2025, at 12:15. This suggests that the momentum of the stock price is shifting towards the downside, with a potential for further decreases in value. Sellers currently dominate the market, and it is likely that this bearish momentum will continue.

Corbus Pharmaceuticals Holdings Inc. (CRBP) saw its stock price rally 5.71% to $8.52 on Wednesday, outperforming several competitors during an overall positive trading session for the stock market [1]. The NASDAQ Composite Index (COMP) rose 0.25% to 20,730.49, while the Dow Jones Industrial Average (DJIA) climbed 0.53% to 44,254.78. Despite the market's gains, Corbus closed 86.24% below its 52-week high of $61.90, reached on July 31st.

On July 18, 2025, at 12:15, the 15-minute chart of Corbus exhibited a bearish trend, as indicated by a KDJ Death Cross and a Bearish Marubozu pattern [2]. These technical indicators suggest that the stock price momentum is shifting towards the downside, with potential for further decreases in value. Sellers currently dominate the market, indicating that this bearish momentum may continue.

In comparison, Vanda Pharmaceuticals Inc. (VNDA) rose 1.05% to $4.81, Fortress Biotech Inc. (FBIO) gained 1.55% to $1.97, and Viking Therapeutics Inc. (VKTX) increased 3.03% to $31.63. Corbus's performance on Wednesday was notable, as it outperformed these competitors despite the bearish technical indicators.

Trading volume for Corbus was 78,471, remaining 82,713 below its 50-day average volume of 161,184. This suggests that while interest in the stock remains, it is not at its peak.

References:
[1] https://www.marketwatch.com/data-news/corbus-pharmaceuticals-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-060d1719-700562c9a7a0
[2] (Provided Writing Topic)

Comments



Add a public comment...
No comments

No comments yet